Company · AQST
Aquestive Therapeutics, Inc.
Nasdaq's symbol directory lists AQST on Nasdaq as “Aquestive Therapeutics, Inc. - Common Stock”.
In the 12 months to Nov 19, 2026: insiders bought on 1 occasion ($99K); insiders sold on 9 occasions ($734K); 3 planned-sale notices; 2 filings by holders of 5% or more; 9 company reports (Form 8-K, since May 26, 2026).
Insider trades · SEC Form 4
Those inside the hall
Open-market purchases and sales only. Legs one person filed for one day are combined.
Who traded
- Barber Daniel, President and CEO sold $537K
- Krop Julie sold $125K
- Daly Richard J bought $99K
- Korczynski Sherry, Chief Commercial Officer sold $46K
- Davis Matthew W., Chief Development Officer sold $26K
Every trade (10)
- SELLDavis Matthew W., Chief Development Officer sold $26K
- BUYDaly Richard J bought $99K
- SELLBarber Daniel, President and CEO sold $106K
- SELLBarber Daniel, President and CEO sold $120K
- SELLKorczynski Sherry, Chief Commercial Officer sold $46K
- SELLBarber Daniel, President and CEO sold $107K
- SELLBarber Daniel, President and CEO sold $82K
- SELLBarber Daniel, President and CEO sold $19K
- SELLKrop Julie sold $125K
- SELLBarber Daniel, President and CEO sold $104K
Planned sales · SEC Form 144
Notice given
A Form 144 is filed before an insider sells restricted stock. It states an intent; the sale, if it happens, appears later on a Form 4. Every recent notice
- MATTHEW W DAVIS $26K
- Daniel Barber $244K
- Sherry M. Korczynski $46K
Large holders · SEC Schedules 13D and 13G
Five percent and over
Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G
- Bass Edward P 7.5%
- BRATTON DOUGLAS K 0.6%
Company reports · SEC Form 8-K
In its own words
Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.
- Regulation FD disclosure Nov 16, 2026
- Regulation FD disclosure Nov 5, 2026
- Results of operations and financial condition; Regulation FD disclosure Nov 3, 2026
- Amendments to articles or bylaws; change in fiscal year Oct 19, 2026
- Regulation FD disclosure Oct 15, 2026
- Entry into a material definitive agreement Oct 14, 2026
- Departure or appointment of directors or officers Sep 29, 2026
- Regulation FD disclosure Sep 25, 2026
- Regulation FD disclosure; Other events Sep 17, 2026
Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.